No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients

No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients

The influence of treatment with alendronate (ALN), teriparatide (TPTD) or concurrent treatment with both on the human bone matrix mineralization has not yet been fully elucidated. For this purpose we analyzed quadruple fluorochrome labelled transiliac bone biopsy samples (n = 66) from postmenopausal...

Full description

Bibliographic Details
Main Authors: Barbara M. Misof, Paul Roschger, Hua Zhou, Jeri W. Nieves, Mathias Bostrom, Felicia Cosman, Robert Lindsay, Klaus Klaushofer, David W. Dempster
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Bone Reports
Subjects:
Bone matrix mineralization
Combined therapy with alendronate and teriparatide
Quadruple labelling
Secondary mineralization
Transiliac bone biopsy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187220300139

Internet

http://www.sciencedirect.com/science/article/pii/S2352187220300139

Similar Items